166 related articles for article (PubMed ID: 36971916)
1. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
[TBL] [Abstract][Full Text] [Related]
2. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
Wu X; Li J; Zhou Y; Mao Y; Luo S; He X; Wang L; Shen Y; Zhang H; Yang L; Zhang J
Chemotherapy; 2018; 63(6):301-307. PubMed ID: 30836365
[TBL] [Abstract][Full Text] [Related]
3. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
[TBL] [Abstract][Full Text] [Related]
4. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
[TBL] [Abstract][Full Text] [Related]
5. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
6. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
8. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
[TBL] [Abstract][Full Text] [Related]
10. Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning.
Ran P; Tan T; Li J; Yang H; Li J; Zhang J
BMC Cancer; 2024 Feb; 24(1):264. PubMed ID: 38402382
[TBL] [Abstract][Full Text] [Related]
11. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
12. Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level.
Wu X; Ge Y; He X; Li J; Zhang J
Front Surg; 2023; 10():1115141. PubMed ID: 36911619
[TBL] [Abstract][Full Text] [Related]
13. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.
Zeng L; Cheng X; Li J; Zhang J; Wu X
PLoS One; 2024; 19(5):e0303290. PubMed ID: 38743680
[TBL] [Abstract][Full Text] [Related]
14. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
[TBL] [Abstract][Full Text] [Related]
15. Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Chen H; Liu J; Zhou Y; Hou Y; Ma G; Cai W
Ther Drug Monit; 2019 Oct; 41(5):582-590. PubMed ID: 31045869
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.
Liu M; Guo T; Ma Z; Du L; Hou J; Tian Y; Meng M; Chen X
Ther Drug Monit; 2024 Jun; 46(3):344-350. PubMed ID: 38176855
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.
Huang W; Li J; Qiu F; Wu X; Zhang J; Li X; Yao G; Zhu S
J Clin Pharm Ther; 2020 Aug; 45(4):856-862. PubMed ID: 32479700
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
19. Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
Xu J; Ling TL; Wang M; Zhao WY; Cao H
Int Surg; 2015 May; 100(5):860-9. PubMed ID: 26011207
[TBL] [Abstract][Full Text] [Related]
20. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
